Every 424B that Recursion Pharmaceuticals, Inc. (RXRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow RXRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RXRX filings page.
Recursion Pharmaceuticals, Inc. (RXRX) is offering 61,540,000 Class A common shares at $3.25 each, for a total offering price of $200,005,000. Estimated net proceeds are approximately $187.2 million after underwriting discounts and commissions and estimated offering expenses. The company intends to use proceeds for preclinical and clinical programs, platform technologies, runway extension, strategic investments and acquisitions, and general corporate purposes.
Preliminary cash, cash equivalents and restricted cash were approximately $561 million as of September 30, 2026, subject to closing procedures and quarterly review. Recursion expects its existing cash resources plus offering proceeds to fund operating expenses and capital expenditures into 2029. The offering states immediate dilution of approximately $2.21 per share in net tangible book value for new investors.
REC-4881 showed a 47% median reduction in total polyp burden at week 13 among 16 efficacy-evaluable patients; 85% (11 of 13) remained below baseline after 12 weeks off treatment. For REC-1245, 11 of 12 patients who started at 45 mg or 65 mg achieved disease control at eight weeks; Recursion selected 45 mg for monotherapy expansion. Sanofi optioned a first development candidate from its collaboration with Recursion, triggering a $10 million milestone; Recursion remains eligible for more than $300 million in additional program milestones.
Recursion Pharmaceuticals, Inc. (RXRX) is offering $200,000,000 of Class A common stock. It intends to use net proceeds for preclinical and clinical programs, platform technologies, runway extension, strategic investments and acquisitions, and general corporate purposes. Recursion expects existing cash and offering proceeds to fund operating expenses and capital requirements into 2029.
Preliminary cash, cash equivalents and restricted cash were approximately $561 million as of September 30, 2026, including approximately $86 million in net proceeds from 23,696,330 shares sold through its at-the-market program during the quarter. Sanofi optioned a development candidate, triggering a $10 million milestone and bringing collaboration upfront and milestone payments to $144 million to date. Recursion remains eligible for more than $300 million in additional milestones and low-double-digit average royalties on net product sales if the candidate is successfully commercialized.
In REC-4881, 16 efficacy-evaluable patients had a 47% median reduction in total polyp burden at week 13; 85% (11 of 13) remained below baseline after twelve weeks off treatment. In REC-1245, 11 of 12 patients starting at 45 mg or 65 mg achieved disease control at eight weeks, and 45 mg daily was selected for monotherapy expansion.
Recursion Pharmaceuticals filed a prospectus supplement establishing an at-the-market offering to sell shares of its Class A Common Stock having an aggregate offering price of up to $300,000,000. Sales may be made from time to time through TD Securities (USA) LLC (TD Cowen) as agent or principal.
The prospectus states the offering may include negotiated transactions, block trades or any method permitted by law and that TD Cowen may receive compensation up to 3% of gross proceeds. The last reported sale price of the Class A Common Stock was $3.53 per share on February 24, 2026. The prospectus illustration assumes sale of 84,985,835 shares for aggregate proceeds of $300,000,000, resulting in up to 606,816,881 shares outstanding (based on 521,831,046 shares outstanding as of December 31, 2025).
Recursion Pharmaceuticals, Inc. is registering up to 7,088,742 shares of its Class A Common Stock for potential resale from time to time by Tempus AI, Inc. and its permitted transferees. These shares were issued to Tempus on November 24, 2025 as payment in kind for a $32 million 2025 annual license fee under a data and services agreement, at a per share price of $4.5142.
Recursion will not sell any shares in this offering and will not receive proceeds from any resale by Tempus, though it will cover registration expenses. As context, there were 514,190,251 shares of Class A Common Stock and 5,647,334 shares of Class B Common Stock outstanding as of November 24, 2025. The filing satisfies Recursion’s contractual obligation to provide resale registration for the Tempus shares.